RxDoctor Payments Data

Geraldo Ramos, MD

Cardiovascular Disease · St. Petersburg, FLNPI 1881845543

Payments from drug & device makers

$116,547in general payments, 2019–2025

Across 512 payments — averaging $227.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$51K
  • AstraZeneca$35K
  • Lilly USA, LLC$17K
  • Lexicon Pharmaceuticals, Inc.$7K
  • Novo Nordisk$800
  • Johnson & Johnson$696
  • plus $6K from 22 others

What the payments were for

  • Consulting fees$4,1254%
  • Speaking & faculty fees$97,57384%
  • Travel & lodging$1,6891%
  • Food & beverage$13,11311%
  • Education$480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,547 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$331,675
Medicare patients
1,500
Services billed
4,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban578$635,847
JardianceEmpagliflozin300$380,968
FarxigaDapagliflozin Propanediol249$261,059
XareltoRivaroxaban213$243,715
OzempicSemaglutide126$147,212
EntrestoSacubitril/Valsartan104$135,444
MultaqDronedarone Hcl26$59,923
MounjaroTirzepatide28$29,920
Repatha SureclickEvolocumab28$20,445
BrilintaTicagrelor21$15,273
DapagliflozinDapagliflozin Propanediol22$12,798
Carvedilol407$4,385
Metoprolol Succinate289$3,621
Atorvastatin Calcium356$3,575
Diltiazem 24hr Er (Cd)Diltiazem Hcl88$2,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$635,847578 claims
Boehringer IngelheimJardiance$50,833$380,968300 claims
AstraZenecaFarxiga, Brilinta$34,662$276,332270 claims
Johnson & JohnsonXarelto$696$243,715213 claims
Novo NordiskOzempic$800$147,212126 claims
NovartisEntresto$531$135,444104 claims
Sanofi-aventis U.S. LLCMultaq$265$59,92326 claims
Lilly USA, LLCMounjaro$16,509$29,92028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in St. Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →